# US 2015/0105352 A1 · Combination of an hmg-coa reductase inhibitor and a farnesyl-pyrophosphatase synthase inhibitor for the treatment of diseases related to the persistence and/or accumulation of prenylated proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105352 A1
- Document ID: US20150105352A1
- Status: Published application
- Kind: A1
- Application number: 14/575,814
- Filed: 2014-12-18
- Published: 2015-04-16
- Earliest claimed: 2006-07-05
- Assignees: Universite D'Aix-Marseille; Association Francaise Contre Les Myopathies (Afm); Assistance Publique - Hopitaux De Marseille; Universidad De Oviedo
- Applicants: Universitè D'Aix-Marseille; Association Francaise Contre Les Myopathies (Afm); Assistance Publique Hopitaux De Marseille; Universidad De Oviedo
- Inventors: Nicolas LEVY; Pierre CAU; Carlos LOPEZ-OTIN
- Web page: https://patentgrep.com/patent/US20150105352A1

## CPC

- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 8/4913: {having five membered rings, e.g. pyrrolidone carboxylic acid}
- A61K 8/498: {having 6-membered rings or their condensed derivatives, e.g. coumarin}
- A61K 8/55: Phosphorus compounds
- A61K 31/215: of carboxylic acids
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/663: Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/16: Emollients or protectives, e.g. against radiation
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61Q 19/08: Anti-ageing preparations
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The invention relates to the use of a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and of a farnesyl-pyrophosphate synthase inhibitor, or of one of their associated physiologically acceptable salts, in the preparation of a composition, particularly a pharmaceutical composition, for use in the treatment of human or animal, pathological or nonpathological situations related to the accumulation and/or the persistence of prenylated proteins in cells, such as during progeria (Hutchinson-Gilford syndrome), restrictive dermopathy or physiological ageing.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A method of treating a condition selected from the group consisting of skin aging, premature skin aging, progeria, lipodystrophy, and restrictive dermopathy, the method comprising administering to a subject in need thereof an effective amount of a combination comprising:
at least one inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, and
at least one inhibitor of farnesyl pyrophosphate synthase.

### Claim 17 (depends on 16)

The method of claim 16, wherein the HMG-CoA reductase inhibitor is a statin or a physiologically-acceptable salt thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein the HMG-CoA reductase inhibitor is a water-soluble statin.

### Claim 19 (depends on 17)

The method of claim 17, wherein the HMG-CoA reductase inhibitor is selected from the group consisting of atorvastatin, simvastatin, pravastatin, rivastatin, mevastatin (or compactin), fluindostatin, velostatin, fluvastatin, dalvastatin, cerivastatin, pentostatin, rosuvastatin, lovastatin, pitavastatin, and physiologically-acceptable salts thereof.

### Claim 20 (depends on 16)

The method of claim 16, wherein the farnesylpyrophosphate synthase inhibitor is an aminobiphosphonate (NBP) or a physiologically-acceptable salt thereof.

### Claim 21 (depends on 20)

The method of claim 20, wherein the aminobiphosphonate is selected from the group consisting of:
alendronic acid or the ionic form thereof, alendronate;
clodronic acid or the ionic form thereof, clodronate;
etidronic acid or the ionic form thereof, etidronate;
ibandronic acid or the ionic form thereof, ibandronate;
medronic acid or the ionic form thereof, medronate;
neridronic acid or the ionic form thereof, neridronate;
olpadronic acid or the ionic form thereof, olpadronate;
pamidronic acid or the ionic form thereof, pamidronate;
risedronic acid or the ionic form thereof, risedronate;
tiludronic acid or the ionic form thereof, tiludronate;
zoledronic acid or the ionic form thereof, zoledronate;
4-N,N-dimethylaminomethane diphosphonic acid or the ionic form thereof, dimethylaminomethanediphosphonate; and
α-amino-(4-hydroxybenzylidene)diphosphonate.

### Claim 22 (depends on 21)

The method of claim 21, wherein the farnesylpyrophosphate synthase inhibitor is zoledronic acid or the ionic form thereof, zoledronate.

### Claim 23 (depends on 16)

The method of claim 16, wherein the premature skin ageing is not related to a genetic mutation in an LMNA gene.

### Claim 24

A composition comprising a synergistically-effective amount of a combination of:
at least one inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, and
at least one inhibitor of farnesyl pyrophosphate synthase,
wherein the composition is used in the treatment of conditions selected from the group consisting of skin aging, premature skin aging, premature myolipocutaneous aging, progeria, lipodystrophy, and restrictive dermopathy.

### Claim 25 (depends on 24)

The composition of claim 24, wherein the HMG-CoA reductase inhibitor is a statin or a physiologically-acceptable salt thereof.

### Claim 26 (depends on 25)

The composition of claim 25, wherein the HMG-CoA reductase inhibitor is a water-soluble statin.

### Claim 27 (depends on 25)

The composition of claim 25, wherein the HMG-CoA reductase inhibitor is selected from the group consisting of atorvastatin, simvastatin, pravastatin, rivastatin, mevastatin (or compactin), fluindostatin, velostatin, fluvastatin, dalvastatin, cerivastatin, pentostatin, rosuvastatin, lovastatin, pitavastatin, and physiologically-acceptable salts thereof.

### Claim 28 (depends on 24)

The composition of claim 24, wherein the farnesylpyrophosphate synthase inhibitor is an aminobiphosphonate (NBP) or a physiologically-acceptable salt thereof.

### Claim 29 (depends on 28)

The composition of claim 28, wherein the aminobiphosphonate is selected from the group consisting of:
alendronic acid or the ionic form thereof, alendronate;
clodronic acid or the ionic form thereof, clodronate;
etidronic acid or the ionic form thereof, etidronate;
ibandronic acid or the ionic form thereof, ibandronate;
medronic acid or the ionic form thereof, medronate;
neridronic acid or the ionic form thereof, neridronate;
olpadronic acid or the ionic form thereof, olpadronate;
pamidronic acid or the ionic form thereof, pamidronate;
risedronic acid or the ionic form thereof, risedronate;
tiludronic acid or the ionic form thereof, tiludronate;
zoledronic acid or the ionic form thereof, zoledronate;
4-N,N-dimethylaminomethane diphosphonic acid or the ionic form thereof, dimethylaminomethanediphosphonate; and
α-amino-(4-hydroxybenzylidene)diphosphonate.

### Claim 30 (depends on 29)

The composition of claim 29, wherein the farnesylpyrophosphate synthase inhibitor is zoledronic acid or the ionic form thereof, zoledronate.

### Claim 31 (depends on 24)

The composition of claim 24, wherein the premature skin aging is not related to a genetic mutation in an LMNA gene.

### Claim 32

A method for the treatment of a skin disorder related to the accumulation of farnesylated and/or geranylgeranylated protein in skin cells, wherein the skin disorder is selected from the group consisting of natural skin aging, premature skin aging not related to a genetic mutation, and lipodystrophy, the method comprising the step of administering to an individual in need thereof an effective amount of at least one inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, and at least one aminobisphosphonate,
wherein the HMG-CoA reductase inhibitor is selected from the group consisting of atorvastatin, simvastatin, pravastatin, rivastatin, mevastatin, fluindostatin, velostatin, fluvastatin, dalvastatin, cerivastatin, pentostatin, rosuvastatin, lovastatin, pitavastatin, and physiologically-acceptable salts thereof;
wherein the aminobiphosphonate is selected from the group consisting of alendronic acid or the ionic form thereof, ibandronic acid or the ionic form thereof, neridronic acid or the ionic form thereof, olpadronic acid or the ionic form thereof, risedronic acid or the ionic form thereof, zoledronic acid or the ionic form thereof, icandronic acid or the ionic form thereof, minodronic acid or the ionic form thereof, 4-N,N-dimethylaminomethane diphosphonic acid or the ionic form thereof, and α-amino-(4-hydroxybenzylidene)diphosphonate;
wherein the amount of the HMG-CoA reductase inhibitor and amount of aminobisphosphonate have a synergistic effect on reducing the accumulation of farnesylated and/or geranylgeranylated protein in skin cells; and
wherein the HMG-CoA reductase inhibitor and aminobisphosphonate are formulated for administration on the skin.

### Claim 33 (depends on 32)

The method of claim 32, wherein the aminobisphosphonate is zoledronic acid or the ionic form thereof.

### Claim 34 (depends on 32)

The method of claim 32, wherein the premature skin aging is not related to a genetic mutation in an LMNA gene.

### Claim 35 (depends on 32)

The method of claim 32, wherein the HMG-CoA reductase inhibitor is a statin or a physiologically-acceptable salt thereof.

### Claim 36 (depends on 35)

The method of claim 35, wherein the HMG-CoA reductase inhibitor is a water-soluble statin.

### Claim 37 (depends on 35)

The method of claim 35, wherein the HMG-CoA reductase inhibitor is selected from the group consisting of atorvastatin, simvastatin, pravastatin, rivastatin, mevastatin (or compactin), fluindostatin, velostatin, fluvastatin, dalvastatin, cerivastatin, pentostatin, rosuvastatin, lovastatin, pitavastatin, and physiologically-acceptable salts thereof.

### Claim 38 (depends on 32)

The method of claim 32, wherein the farnesylpyrophosphate synthase inhibitor is an aminobiphosphonate (NBP) or a physiologically-acceptable salt thereof.

### Claim 39 (depends on 38)

The method of claim 38, wherein the aminobiphosphonate is selected from the group consisting of:
alendronic acid or the ionic form thereof, alendronate;
clodronic acid or the ionic form thereof, clodronate;
etidronic acid or the ionic form thereof, etidronate;
ibandronic acid or the ionic form thereof, ibandronate;
medronic acid or the ionic form thereof, medronate;
neridronic acid or the ionic form thereof, neridronate;
olpadronic acid or the ionic form thereof, olpadronate;
pamidronic acid or the ionic form thereof, pamidronate;
risedronic acid or the ionic form thereof, risedronate;
tiludronic acid or the ionic form thereof, tiludronate;
zoledronic acid or the ionic form thereof, zoledronate;
4-N,N-dimethylaminomethane diphosphonic acid or the ionic form thereof, dimethylaminomethanediphosphonate; and
α-amino-(4-hydroxybenzylidene)diphosphonate.

### Claim 40

A composition comprising a synergistically-effective amount of a combination of:
at least one HMG-CoA reductase inhibitor selected from the group consisting of atorvastatin, simvastatin, pravastatin, rivastatin, mevastatin, fluindostatin, velostatin, fluvastatin, dalvastatin, cerivastatin, pentostatin, rosuvastatin, lovastatin, pitavastatin, and one of the physiologically-acceptable salts thereof;
at least one aminobiphosphonate selected from the group consisting of alendronic acid or the ionic form thereof, ibandronic acid or the ionic form thereof, neridronic acid or the ionic form thereof, olpadronic acid or the ionic form thereof, risedronic acid or the ionic form thereof, zoledronic acid or the ionic form thereof, icandronic acid or the ionic form thereof, minodronic acid or the ionic form thereof, 4-N,N-dimethylaminomethane diphosphonic acid or the ionic form thereof, and α-amino-(4-hydroxybenzylidene)diphosphonate;
said composition formulated for administration on the skin,
wherein the amount of the HMG-CoA reductase inhibitor and amount of aminobisphosphonate have a synergistic effect on reducing the accumulation of farnesylated and/or geranylgeranylated protein in skin cells; and
wherein the composition is administered for the treatment of a skin disorder related to the accumulation of farnesylated and/or geranylgeranylated protein in skin cells, selected from the group consisting of natural skin aging, premature skin ageing not related to a genetic mutation and lipodystrophy.
